![]() |
|
Linus Health to Present Six Studies at CTAD 2026 - Printable Version +- HIStalk Sponsor Announcements (https://histalk.com/forum) +-- Forum: Sponsor News (https://histalk.com/forum/forumdisplay.php?fid=1) +--- Forum: Announcements (https://histalk.com/forum/forumdisplay.php?fid=2) +--- Thread: Linus Health to Present Six Studies at CTAD 2026 (/showthread.php?tid=2344) |
Linus Health to Present Six Studies at CTAD 2026 - Supreme Communications - 11-17-2026 Linus Health to Present Six Studies at CTAD 2026 on Detection of Cognitive Impairment, Amyloid Prediction, and Patient-Centered Outcomes
Studies presented at the premier global forum for Alzheimer's disease clinical research span digital cognitive assessment validation, amyloid PET prediction, claims-based dementia risk stratification, and patient-defined outcomes
BOSTON, Nov. 16, 2026 -- Linus Health, an AI-driven brain health company focused on early detection and proactive intervention, will present six scientific posters at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place today through Nov. 19 in Boston. The studies evaluate Linus Health's AI-enabled digital cognitive assessments, its Radar™ dementia risk model, and its electronic Person-Specific Outcome Measure (ePSOM). The findings support the use of the company's technologies to help clinicians and trial sponsors identify earlier the individuals who may benefit from further evaluation for Alzheimer's disease trials or therapies, and measure the benefits that matter most to patients. Two of the posters focus on Linus Cognitive Assess, formerly the Digital Clock and Recall (DCR™), a brief tablet-based assessment that pairs the DCTclock™ digital clock-drawing test with word recall. Two more examine Linus Cognitive Profile, formerly the Digital Assessment of Cognition (DAC), a seven-minute speech-based assessment of memory, working memory, and category fluency, including its ability to predict amyloid status on positron emission tomography (PET). The remaining posters report on the ePSOM in Japan and on an updated version of Radar, which estimates dementia risk from claims data. The research arrives as an estimated 7.4 million Americans age 65 and older are living with Alzheimer's dementia, according to the Alzheimer's Association's 2026 Facts and Figures report. As new disease-modifying therapies reach more patients, clinical trials are also enrolling participants earlier in the disease. Both shifts require tools that quickly and accurately identify eligible individuals, along with measures that help assess whether treatment effects are meaningful to patients in their daily lives. "Alzheimer's research and routine clinical care increasingly depend on the same foundation of identifying cognitive change early and acting on it with confidence," said David Bates, PhD, CEO and Co-Founder of Linus Health. "Many health systems are building brain health programs to prepare for more patients who may qualify for new therapies, while drug developers need faster enrollment of more representative trial populations. CTAD brings both communities together and is a natural place to share the evidence behind validated digital tools that can scale from a local health system to a global clinical trial." The amyloid PET and Radar posters will be on display from 2 p.m. today through 5:30 p.m. tomorrow, and the other four on Thursday, Nov. 19, from 7:15 a.m. to 5 p.m. (all Eastern Time). Titles and highlights from the poster presentations include:
"This is the third consecutive year Linus Health scientists have presented multiple studies at CTAD," said Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health. "Our technologies are supported by more than 160 peer-reviewed papers, and we share new findings each year at leading international meetings, including the Alzheimer's Association International Conference (AAIC) and the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD). Clinicians and trial sponsors need to see a digital assessment demonstrate validity, reliability, and clinical utility through rigorous research before they rely on it, and we intend to keep holding our work to that standard." Alongside the poster presentations, Linus Health scientists will be available throughout the conference to meet and discuss the use of the company's digital assessments to support trial recruitment, strengthen outcome measures, and generate real-world evidence in Alzheimer's research. Click here to schedule a meeting with Linus Health at CTAD 2026. About Linus Health Linus Health is a Boston-based digital health company focused on improving brain health around the world. The company develops science-driven digital assessments and AI-enabled analytics that help clinicians and researchers identify cognitive change earlier, guide next steps in care, and support more proactive, personalized intervention. Linus Health works with healthcare delivery organizations, research institutions, and life sciences partners to advance earlier detection and better brain health outcomes. To learn more, visit www.linushealth.com or follow Linus Health on LinkedIn. Media Contact Supreme Communications for Linus Health LinusHealthPR@supremecomms.ai |